Early Oral Hydration in Relieving Postoperative Thirst
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorSindh Institute of Urology and Transplantation
About this trial
This study aims to evaluate whether allowing early oral hydration on demand effectively relieves postoperative thirst and enhances patient satisfaction in individuals undergoing urological endoscopic procedures
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Male and female patients aged 18-65 years.
Scheduled for elective urological endoscopic procedures under general anesthesia.
Day-care endoscopic procedures.
ASA classification I-III.
Disqualifiers
Known gastrointestinal disorders contraindicating early oral hydration (e.g., peptic ulcer disease, hiatal hernia, irritable bowel syndrome, esophagitis, or prior gastrointestinal surgery).
Inability to express thirst or communicate (e.g., language barrier, altered consciousness).
Requirement for nasogastric suction.
History of facial, oropharyngeal, or laryngeal surgery.
Trial design
Design model
Parallel
Treatments tested in this trial
Early oral hydration
Dietary supplement"Early oral hydration" refers to the administration of small sips of water (maximum 10 mL initially) within 15-30 minutes of arrival in the PACU, once the patient is fully conscious, stable, and meets safety criteria. Initially, patients will be provided a maximum of 10 mL of water using a straw. After this initial intake, they will be allowed to drink water according to their demand, provided their condition remains stable. To minimize the risk of adverse events such as regurgitation and aspiration, the total amount of water intake will be restricted to 0.5 mL/kg.
No early oral hydration (As per Standard PACU Protocol)
Other interventionPatients in the control group will follow the standard PACU protocol, which will delay oral hydration for 2-3 hours after the end of anesthesia. During this period, patients will be monitored closely for thirst and other postoperative symptoms.
Treatment groups
200 Participants
are divided into 2 treatment groupsGroup A: EOH Group (Early Oral Hydration)Experimental treatment 1 intervention
Group B: Control Group (Standard PACU Protocol)Active comparator 1 intervention
Trial outcomes
Primary outcomes
1
Thirst intensity upon PACU arrival
Patients will be asked Did you experience thirst upon arrival in the PACU? * Yes * No If yes, rate your thirst intensity upon PACU arrival using the Visual Analogue Scale (VAS) on PACU entry. 0 = No thirst, 10 = Worst imaginable thirst \[0---1---2---3---4---5---6---7---8---9---10\]
Time frame
Up to 2 hours during immediate post-operative period2
Thirst intensity at PACU discharge
Patients will be asked Did you experience thirst at PACU discharge? * Yes * No If yes, rate your thirst intensity at PACU discharge using the VAS (0-10). 0 = No thirst, 10 = Worst imaginable thirst \[0---1---2---3---4---5---6---7---8---9---10\]
Time frame
Up to 2 hours during immediate post-operative period3
Patient comfort
Rate your comfort level during the PACU stay using the VAS (0-10) (0 = Uncomfortable, 10 = Very comfortable) \[0---1---2---3---4---5---6---7---8---9---10\]
Time frame
Up to 2 hours during immediate post-operative period4
Patient satisfaction with the hydration timing.
How satisfied are you with the hydration timing? (5-point Likert Scale): * Very Dissatisfied * Dissatisfied * Neutral * Satisfied * Very Satisfied
Time frame
Up to 2 hours during immediate post-operative periodSecondary outcomes
1
Adverse Events
Do you experience any of the following adverse events after drinking water? (Check all that apply): * Bucking * Aspiration * Vomiting * None
Time frame
Up to 2 hours during immediate post-operative period2
Medical intervention given for any adverse event
Is medical intervention given for any adverse event? * Yes (specify: \_\_\_\_\_\_\_\_\_\_\_\_\_) * No
Time frame
Up to 2 hours during immediate post-operative periodSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov